Unity Biotechnology (NASDAQ:UBX) Receives Outperform Rating from Wedbush

Wedbush restated their outperform rating on shares of Unity Biotechnology (NASDAQ:UBX – Get Rating) in a report published on Thursday morning, Benzinga reports. Wedbush currently has a $35.00 price objective on the stock.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reissued a buy rating and issued a $10.00 price target on shares of Unity Biotechnology in a report on Wednesday, February 15th. Mizuho lowered their price target on Unity Biotechnology from $80.00 to $12.00 and set a buy rating for the company in a report on Wednesday, November 16th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of Buy and an average target price of $34.25.

Unity Biotechnology Stock Performance

Shares of NASDAQ UBX opened at $3.78 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.92 and a quick ratio of 6.12. The business has a 50-day simple moving average of $4.31 and a two-hundred day simple moving average of $3.86. Unity Biotechnology has a fifty-two week low of $2.09 and a fifty-two week high of $18.50.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Prime Capital Investment Advisors LLC purchased a new position in shares of Unity Biotechnology in the fourth quarter worth about $31,000. Virtu Financial LLC raised its stake in shares of Unity Biotechnology by 25.4% in the second quarter. Virtu Financial LLC now owns 62,640 shares of the company’s stock worth $35,000 after purchasing an additional 12,681 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Unity Biotechnology in the fourth quarter worth about $37,000. Schonfeld Strategic Advisors LLC purchased a new position in Unity Biotechnology during the fourth quarter valued at approximately $38,000. Finally, Maven Securities LTD purchased a new position in Unity Biotechnology during the third quarter valued at approximately $40,000.

About Unity Biotechnology

(Get Rating)

Unity Biotechnology, Inc operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.